CRM vs MRK: Which Is the Better Buy?
Side-by-side comparison of Salesforce, Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
Salesforce, Inc. · Technology
$181.22
+161.6% upside to fair value
High Conviction
Grade A-
VS
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
CRM has more upside to fair value
(+161.6%).
MRK trades at a lower forward P/E
(14.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRM |
MRK |
| Current Price |
$181.22 |
$121.42 |
| Fair Value Estimate |
$474.00 |
$118.00 |
| Upside to Fair Value |
+161.6%
|
-2.9%
|
| Market Cap |
$169.8B |
$300.2B |
| Forward P/E |
22.7x
|
14.0x
|
| EV / EBITDA |
—
|
11.8x
|
| Price / Sales |
4.1x
|
4.1x
|
| Price / FCF |
11.8x
|
21.4x
|
| Revenue Growth YoY |
+9.2%
|
+1.3%
|
| Gross Margin |
77.7%
|
81.5%
|
| Operating Margin |
21.5%
|
41.2%
|
| Return on Equity |
12.4%
|
34.7%
|
| Dividend Yield |
— |
3.1% |
| FCF Yield |
8.5%
|
4.7%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Salesforce is the leading global provider of CRM software, offering a strong competitive moat through market dominance and high switching costs, complemented by acquisitions like Slack and Tableau, with excellent margins above 77% gross and robust free cash flow of $15.16 per share. Despite decelerating revenue growth at 9.2% YoY and negative earnings growth of -6.9%, the business remains high-qu…
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
Accumulation Zones
| Metric |
CRM |
MRK |
| Zone Low |
$356.00 |
$88.00 |
| Zone High |
$403.00 |
$100.00 |
| In Buy Zone? |
Yes
|
No
|